Press release
Retinal Vein Occlusion Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Retinal Vein Occlusion Treatment Landscape. Click here to read more @ Retinal Vein Occlusion Pipeline Outlook [https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Retinal Vein Occlusion Pipeline Report
* In July 2025, Retina Research Institute LLC announced a clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain. Receive one drop of the topical drops five minutes prior to their regularly scheduled intravitreal injection. Depending on the treatment arm, they will also administer drops on their own at home up to 3 times per day on the day of their procedure.
* DelveInsight's Retinal Vein Occlusion Pipeline analysis depicts the space with 15+ active players working to develop 15+ pipeline therapies.
* The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
* Promising Retinal Vein Occlusion Pipeline Therapies include Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept , and others.
For further information, refer to the detailed Retinal Vein Occlusion Drugs Launch, Drugs Developmental Activities, and News, click here @ Retinal Vein Occlusion Ongoing Clinical Trial Analysis [https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Retinal Vein Occlusion Emerging Drugs
* KSI-301: Kodiak sciences
The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.
* 601: Sunshine Guojian Pharmaceutical
601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.
* IBE-814: Ripple Therapeutics
IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).
The Retinal Vein Occlusion Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment.
* Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion market
Stay informed about the Retinal Vein Occlusion Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Retinal Vein Occlusion Unmet Needs [https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Retinal Vein Occlusion Companies
Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical.
* Molecule Type
Retinal Vein Occlusion Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Transform your understanding of the Retinal Vein Occlusion Pipeline! See the latest progress in drug development and clinical research @ Retinal Vein Occlusion Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Retinal Vein Occlusion Pipeline Report
* Coverage- Global
* Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys , and others.
* Retinal Vein Occlusion Pipeline Therapies- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.
* Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Ophthalmology Research-Access the Full Retinal Vein Occlusion Pipeline Analysis Today! @ Retinal Vein Occlusion Drugs and Companies [https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Retinal Vein Occlusion: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* KSI-301: Kodiak sciences
* Mid Stage Products (Phase II)
* 601: Sunshine Guojian Pharmaceutical
* Early Stage Products (Phase I)
* MHU650: Novartis
* Inactive Products
* Retinal Vein Occlusion Key Companies
* Retinal Vein Occlusion Key Products
* Retinal Vein Occlusion- Unmet Needs
* Retinal Vein Occlusion- Market Drivers and Barriers
* Retinal Vein Occlusion- Future Perspectives and Conclusion
* Retinal Vein Occlusion Analyst Views
* Retinal Vein Occlusion Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinal-vein-occlusion-pipeline-outlook-report-2025-key-15-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinal Vein Occlusion Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4148517 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Retina
Visual Prosthesis Market | Bionic Vision, Nano Retina, PIXIUM VISION, Retina Imp …
The global visual prosthesis market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the visual prosthesis market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Artificial Retina Market Revenue 2019: Nano-Retina, Second Sights
Product innovation is a key artificial retina market trend. The ophthalmic industry has become more competitive over the last few years. Established ophthalmic product categories have become more mature, in turn offering low level of market opportunity for players. Most companies are emphasizing on price level strategy in order to enhance their business presence worldwide. However, the pricing trend could potentially benefit the company on a shorter scale during the…
Artificial Retina Market Key Players – Second Sight, Nano Retina, Retina Impla …
Artificial Retina manufacturers are making huge financial investments in R&D which is leading to new and innovative product development resulting in driving the growth for the market in turn. According to a recent study report published by the Market Research Future, The Global Market of Artificial Retina is growing steadily and is expected to continue its growth soon. Global Artificial Retina Market is expected to grow to US$ 102.9 million…
Artificial Retina Market 2018: Advancement with Key Player – Second Sight, Nan …
Artificial Retina is new hope for blind people and helps blind person to see objects. Artificial retina is placed either in the internal surface of the retina or outer surface of retina. There are around 1.5 million people suffering from retinitis pigmentosa which ultimately causes blindness. Approximately, 280 million people with visual impairment and about 40 million people are completely blind.
Global Artificial Retina Market - Key Players
Some of the…
Artificial Retina Market Insights With Key Players Nano-Retina, Second Sights, a …
Artificial retina market is a major breakthrough in medical devices industry, wherein many universities and leading medical devices companies are conducting research to offer vision to over 285 million visually impaired population worldwide. These devices are mainly nanorod carbon nanotube biomimetic films along with accessory devices such as transmitter and video processing unit (VPU). As such progressive development towards artificial retina is expected to create high ROI for engaged…
Artificial Retina Market Unique Scenario by Key Vendors Like: Second Sight, Nano …
Global Market for Artificial Retina is growing steady and expected to continue its growth near future. Global Artificial Retina Market is expected to grow US$ 102.9 million by 2023 at CAGR of 2.1%.
Global Artificial Retina Market - Key Players
Some of the key players in this market are:
Second Sight (US)
Nano Retina (Israel)
Retina Implant AG (Germany)
Pixium Vision (France)
Bionic Vision Australia
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2812
Global Artificial Retina Market - Segments
Global Artificial Retina…
